scholarly journals Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types

2020 ◽  
Vol 21 (23) ◽  
pp. 9031
Author(s):  
Hidenori Takagi ◽  
Liang Dong ◽  
Morgan D. Kuczler ◽  
Kara Lombardo ◽  
Mitsuharu Hirai ◽  
...  
Keyword(s):  
Metastatic Cancer ◽  
Circulating Tumor Cell ◽  
Cell Capture ◽  
Detection Capability ◽  
Multiple Cancer ◽  
Large Size ◽  
Positive Rate ◽  
Median Diameter ◽  
Cancer Types ◽  
Slit Filter

Circulating tumor cells (CTCs) are a promising biomarker for cancer liquid biopsy. To evaluate the CTC capture bias and detection capability of the slit filter-based CTC isolation platform (CTC-FIND), we prospectively compared it head to head to a selection-free platform (AccuCyte®-CyteFinder® system). We used the two methods to determine the CTC counts, CTC positive rates, CTC size distributions, and CTC phenotypes in 36 patients with metastatic cancer. Between the two methods, the median CTC counts were not significantly different and the total counts were correlated (r = 0.63, p < 0.0001). The CTC positive rate by CTC-FIND was significantly higher than that by AccuCyte®-CyteFinder® system (91.7% vs. 66.7%, p < 0.05). The median diameter of CTCs collected by CTC-FIND was significantly larger (13.0 μm, range 5.2–52.0 vs. 10.4 μm, range 5.2–44.2, p < 0.0001). The distributions of CTC phenotypes (CK+EpCAM+, CK+EpCAM− or CK−EpCAM+) detected by both methods were similar. These results suggested that CTC-FIND can detect more CTC-positive cases but with a bias toward large size of CTCs.

scholarly journals Melanoma-secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis

2019 ◽  
Author(s):  
Kevin Kleffman ◽  
Grace Levinson ◽  
Eitan Wong ◽  
Francisco Galán-Echevarría ◽  
Richard Von-Itter ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Metastasis ◽  
Amyloid Beta ◽  
Metastatic Cancer ◽  
Melanoma Cells ◽  
Brain Parenchyma ◽  
Multiple Cancer ◽  
Cancer Types ◽  
The Brain

SummaryBrain metastasis is a significant cause of morbidity and mortality in multiple cancer types and represents an unmet clinical need. The mechanisms that mediate metastatic cancer growth in the brain parenchyma are largely unknown. Melanoma, which has the highest rate of brain metastasis among common cancer types, is an ideal model to study how cancer cells adapt to the brain parenchyma. We performed unbiased proteomics analysis of melanoma short-term cultures, a novel model for the study of brain metastasis. Intriguingly, we found that proteins implicated in neurodegenerative pathologies are differentially expressed in melanoma cells explanted from brain metastases compared to those derived from extracranial metastases. This raised the exciting hypothesis that molecular pathways implicated in neurodegenerative disorders are critical for metastatic adaptation to the brain.Here, we show that melanoma cells require amyloid beta (Aβ), a polypeptide heavily implicated in Alzheimer’s disease, for growth and survival in the brain parenchyma. Melanoma cells produce and secrete Aβ, which activates surrounding astrocytes to a pro-metastatic, anti-inflammatory phenotype. Furthermore, we show that pharmacological inhibition of Aβ decreases brain metastatic burden.Our results reveal a mechanistic connection between brain metastasis and Alzheimer’s disease – two previously unrelated pathologies, establish Aβ as a promising therapeutic target for brain metastasis, and demonstrate suppression of neuroinflammation as a critical feature of metastatic adaptation to the brain parenchyma.

scholarly journals Application of silicon nitride membrane filters in circulating tumor cell capture

2014 ◽  
Vol 17 (2) ◽  
pp. 35-46
Author(s):  
Van Vinh To ◽  
Thi Phuong Tuyen Dao ◽  
Van Binh Pham ◽  
Duy Hien Tong ◽  
Van Hieu Tran
Keyword(s):  
Silicon Nitride ◽  
Tumor Cells ◽  
Early Stage ◽  
Membrane Filter ◽  
Metastatic Cancer ◽  
Circulating Tumor Cell ◽  
Live Cells ◽  
Cell Capture ◽  
Membrane Filters ◽  
Silicon Nitride Membrane

Circulating tumor cells (CTCs) have been recognized as holding extraordinary potential for disease management in cancer patients including prognostic, therapy, and monitoring disease progression. Sensitive and quick detection of CTC could enable the approach to patients with early-stage and metastatic cancer. The technical challenge in this field consists of finding rare tumor cells (just a few CTCs in 1 ml of blood) and being able to distinguish them from epithelial non-tumor cells and leukocytes. The current methodologies have significant limitations such as low capture efficiency, cannot capture live cells and time consuming. This paper presents the development of a new generation of microfilter for size-based isolation of CTCs in epithelial cancer using silicon nitride membrane filters 0.5 cm by 0.5 cm square sheets with slit shaped pores of 5μm by 15μm. We evaluated the sensitivity and efficiency of CTCs capture in a model system using the MCF-7 cells (breast cancer cells) spiked in the blood from the healthy donors. Preliminary results this research shown that silicon nitride membrane filter is a very good candidate to be CTCs detection platfo.

ApoStream, a novel device for antibody-independent capture of circulating cancercells (CCCs) from blood of patients with various types of cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e13500-e13500
Author(s):  
Vishal Gupta ◽  
Insiya Jafferji ◽  
Miguel Garza ◽  
Sujita Sukumaran ◽  
Jacky Woo ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Cancer Cells ◽  
Laser Scanning ◽  
Mononuclear Cells ◽  
Metastatic Cancer ◽  
Multiple Cancer ◽  
Tumor Biopsy ◽  
Peripheral Blood Mononuclear ◽  
Skov3 Cells ◽  
Cancer Types

e13500 Background: The detection of circulating tumor cells (CTCs) using immunomagnetic EpCAM-based capture methods has been conceptually accepted as a “liquid tumor biopsy”. However, these methods have limited the recovery of CTCs for molecular profiling applications. We developed a novel continuous flow dielectrophoresis field-flow fractionation (DEP-FFF) device, ApoStream for antibody-independent capture of circulating cancer cells (CCCs), with improved recovery across multiple cancer types and preserved viability of CCCs for downstream characterization. Methods: The performance of ApoStream was demonstrated using a low EpCAM expressing cell line, SKOV3. ApoStream was further used to enrich CCCs from various cancer patient blood. Prostate, breast and NSCLC CCCs were stained for cytokeratin (CK), CD45, and DAPI; melanoma CCCs were stained with S100, CD45 and DAPI. CCC enumeration was performed using laser scanning cytometry. Results: In system precision performance studies, average inter-day recovery on the ApoStream was 80.3 ± 3.5%, CV = 4.3% when cancer cells were spiked into buffer, and 78.5 ± 3.0%, CV = 3.3% when cancer cells spiked into ~10 million healthy peripheral blood mononuclear cells (PBMCs). Linearity performance was demonstrated with spiking 5-2600 SKOV3 cells into 10 million PBMCs (R2=1). Cell viability was not affected by processing through ApoStream device. High CCC recovery from metastatic cancer patient blood samples was obtained with counts ranging from 0 - 2630 (NSCLC, n=66), 0 - 3490 (prostate, n=29), 10 - 968 (breast, n=11), and 3 - 3120 (melanoma, n=13) CCCs per 7.5 mL blood. Positive CCC counts were obtained in 90% of NSCLC samples, 93% of prostate cancer samples, 100% breast cancer and melanoma specimens. There were no CK+ cells detected in healthy donor blood controls. Conclusions: Improved CCC recovery from various cancer types was demonstrated with the ApoStream device. ApoStream provides an antibody-independent method for capture of viable CCCs that enables further downstream molecular characterization of rare cells for use in clinical applications. Acknowledgements: Funded by NCI Contract No. HHSN261200800001E.

Anticancer Immunotoxins, Challenges, and Approaches

2020 ◽  
Vol 26 ◽  
Author(s):  
Maryam Dashtiahangar ◽  
Leila Rahbarnia ◽  
Safar Farajnia ◽  
Arash Salmaninejad ◽  
Arezoo Gowhari Shabgah ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Antibody Fragment ◽  
Clinical Use ◽  
Multiple Cancer ◽  
Main Obstacle ◽  
Cancer Types ◽  
Recombinant Immunotoxins ◽  
Cancerous Cells ◽  
High Immunogenicity ◽  
Novel Therapeutic

: The development of recombinant immunotoxins (RITs) as a novel therapeutic strategy has made a revolution in the treatment of cancer. RITs are resulting from the fusion of antibodies to toxin proteins for targeting and eliminating cancerous cells by inhibiting protein synthesis. Despite indisputable outcomes of RITs regarding inhibiting multiple cancer types, high immunogenicity has been known as the main obstacle in the clinical use of RITs. Various strategies have been proposed to overcome these limitations, including immunosuppressive therapy, humanization of the antibody fragment moiety, generation of immunotoxins originated from endogenous human cytotoxic enzymes, and modification of the toxin moiety to escape the immune system. This paper devoted to reviewing recent advances in the design of immunotoxins with lower immunogenicity.

scholarly journals Landscape of Chimeric RNAs in Non-Cancerous Cells

Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 466
Author(s):  
Chen Chen ◽  
Samuel Haddox ◽  
Yue Tang ◽  
Fujun Qin ◽  
Hui Li
Keyword(s):  
Cancer Cells ◽  
Cell Lines ◽  
Drug Targets ◽  
Neoplastic Cell ◽  
Multiple Cancer ◽  
Chimeric Rnas ◽  
Healthy Donors ◽  
Cancer Types ◽  
Chimeric Rna ◽  
Cancerous Cells

Gene fusions and their products (RNA and protein) have been traditionally recognized as unique features of cancer cells and are used as ideal biomarkers and drug targets for multiple cancer types. However, recent studies have demonstrated that chimeric RNAs generated by intergenic alternative splicing can also be found in normal cells and tissues. In this study, we aim to identify chimeric RNAs in different non-neoplastic cell lines and investigate the landscape and expression of these novel candidate chimeric RNAs. To do so, we used HEK-293T, HUVEC, and LO2 cell lines as models, performed paired-end RNA sequencing, and conducted analyses for chimeric RNA profiles. Several filtering criteria were applied, and the landscape of chimeric RNAs was characterized at multiple levels and from various angles. Further, we experimentally validated 17 chimeric RNAs from different classifications. Finally, we examined a number of validated chimeric RNAs in different cancer and non-cancer cells, including blood from healthy donors, and demonstrated their ubiquitous expression pattern.

scholarly journals Learning mutational signatures and their multidimensional genomic properties with TensorSignatures

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Harald Vöhringer ◽  
Arne Van Hoeck ◽  
Edwin Cuppen ◽  
Moritz Gerstung
Keyword(s):  
Somatic Hypermutation ◽  
Excision Repair ◽  
Metastatic Cancer ◽  
Strand Break ◽  
Lymphoid Leukaemia ◽  
Mutational Signatures ◽  
Transcription Start Sites ◽  
Nucleotide Excision ◽  
Cancer Types ◽  
Underlying Processes

AbstractWe present TensorSignatures, an algorithm to learn mutational signatures jointly across different variant categories and their genomic localisation and properties. The analysis of 2778 primary and 3824 metastatic cancer genomes of the PCAWG consortium and the HMF cohort shows that all signatures operate dynamically in response to genomic states. The analysis pins differential spectra of UV mutagenesis found in active and inactive chromatin to global genome nucleotide excision repair. TensorSignatures accurately characterises transcription-associated mutagenesis in 7 different cancer types. The algorithm also extracts distinct signatures of replication- and double strand break repair-driven mutagenesis by APOBEC3A and 3B with differential numbers and length of mutation clusters. Finally, TensorSignatures reproduces a signature of somatic hypermutation generating highly clustered variants at transcription start sites of active genes in lymphoid leukaemia, distinct from a general and less clustered signature of Polη-driven translesion synthesis found in a broad range of cancer types. In summary, TensorSignatures elucidates complex mutational footprints by characterising their underlying processes with respect to a multitude of genomic variables.

Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip

ACS Sensors ◽  
2021 ◽  
Author(s):  
Jing Wang ◽  
Alain Wuethrich ◽  
Richard J. Lobb ◽  
Fiach Antaw ◽  
Abu Ali Ibn Sina ◽  
...  
Keyword(s):  
Extracellular Vesicle ◽  
Multiple Cancer ◽  
Cancer Types

scholarly journals Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1082
Author(s):  
Huitao Liu ◽  
Honglin Luo
Keyword(s):  
Tumor Cells ◽  
Current Knowledge ◽  
Oncolytic Viruses ◽  
Human Enterovirus ◽  
Multiple Cancer ◽  
The Family ◽  
Cancer Types ◽  
Group B ◽  
Type 3 ◽  
Genus Enterovirus

Oncolytic viruses have emerged as a promising strategy for cancer therapy due to their dual ability to selectively infect and lyse tumor cells and to induce systemic anti-tumor immunity. Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent years. CVBs are a group of small, non-enveloped, single-stranded, positive-sense RNA viruses, belonging to species human Enterovirus B in the genus Enterovirus of the family Picornaviridae. Preclinical studies have demonstrated potent anti-tumor activities for CVBs, particularly type 3, against multiple cancer types, including lung, breast, and colorectal cancer. Various approaches have been proposed or applied to enhance the safety and specificity of CVBs towards tumor cells and to further increase their anti-tumor efficacy. This review summarizes current knowledge and strategies for developing CVBs as oncolytic viruses for cancer virotherapy. The challenges arising from these studies and future prospects are also discussed in this review.

Sign in / Sign up

Export Citation Format

Share Document